Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei, Martin Jean Schlumberger, Stefan P Müller et al. · Journal of Clinical Oncology · 2013
PURPOSE: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I. PATIENTS AND METHODS: We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC. Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo. The primary end point was progression-free survival (PFS). Additional outcome measures included tumor response rate, overall survival, and safety. RESULTS: The estimated median PFS was 11.2 months for cabozantinib versus 4.0 months for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001). Prolonged PFS with cabozantinib was observed across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic). Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status. Kaplan-Meier estimates of patients alive and progression-free at 1 year are 47.3% for cabozantinib and 7.2% for placebo. Common cabozantinib-associated adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased weight and appetite, nausea, and fatigue and resulted in dose reductions in 79% and holds in 65% of patients. Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients. CONCLUSION: Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease. This dose of cabozantinib was associated with significant but manageable toxicity.
Cited by 1,217 works. doi:10.1200/jco.2012.48.4659 Open-access PDF
Authors
- Rossella Elisei
- Martin Jean Schlumberger
- Stefan P Müller
- Patrick Schöffski
- Marcia S. Brose
- Manisha H. Shah
- Lisa Francesca Licitra
- Barbara Jarząb
- В. С. Медведев
- Michael Christoph Kreissl
- Bruno Niederle
- Ezra E.W. Cohen
- Lori J. Wirth
- Haythem Y. Ali
- Colin Hessel
- Yifah Yaron
- Douglas Wilmot Ball
- Barry D. Nelkin
- Steven I. Sherman
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Rising Thyroid Cancer Incidence in the United States by Demographic and Tumor Characteristics, 1980-2005
- Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- Mechanisms of adverse effects of anti-VEGF therapy for cancer
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- Impact of Routine Measurement of Serum Calcitonin on the Diagnosis and Outcome of Medullary Thyroid Cancer: Experience in 10,864 Patients with Nodular Thyroid Disorders
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study